


&/,1,&$/[ZIP_CODE]&2/
3URWRFRO1R
7LWOH&

$5DQGRPL]HG'RXEOH%OLQG3ODFHER&RQWUROOHG6WXG\RI'LD]R[LGH
&KROLQH&RQWUROOHG5HOHDVH7DEOHW'&&5LQ3DWLHQWVZLWK3UDGHU:LOOL
6\QGURPH
[STUDY_ID_REMOVED]
(XGUD&71R

9HUVLRQ 2ULJLQDO 1RYHPEHU
 $PHQGPHQW )HEUXDU\
 $PHQGPHQW -XO\
 $PHQGPHQW 1RYHPEHU
 $PHQGPHQW $SULO
 $PHQGPHQWD -XQH

6SRQVRU 6ROHQR7KHUDSHXWLFV,QF

&21),'(17,$/
7KLVGRFXPHQWFRQWDLQVSURSULHW DU\DQGFRQILGHQWLDOLQIRUPDWLRQ RI6ROHQR7KHUDSHXWLFV,QF$FFHSWDQFHRIWKLV
GRFXPHQWFRQVWLWXWHVDJUHHPHQWE\ WKHUHFLSLHQWWKDWQRSUHYLRX VO\XQSXEOLVKHGLQIRUPDWLR QFRQWDLQHG KHUHLQZLOO
EHSXEOLVKHGRUGLVFORVHGZLWKRXWWKHSULRUZULWWHQDSSURYDORI 6ROHQR7KHUDSHXWLFV,QFZLWKWKHH[FHSWLRQWKDW
WKLVGRFXPHQWPD\EHGLVFORVHGW RVWXG\SHUVRQQHOXQGHU\RXUVXSHUYLVLRQZKRQHHGWRNQRZWKHFRQWHQWVIRU
FRQGXFWLQJWKHVWXG\DQGDSSURSULDWH,QVWLWX WLRQDO5HYLHZ%RDUG V,5%V,QGHSHQGHQW(WKLFV&RPPLWWHHV,(&
XQGHUWKHFRQGLWLRQWKDWWKHSHUVRQQHOKDYHDJUHHGWRNHHSWKLV LQIRUPDWLRQFRQILGHQWLDO7KHIRUHJRLQJVKDOOQRW
DSSO\WRGLVFORVXUHUHTXLUHGE\JRYHUQPHQWDOUHJXODWLRQVRUODZ VKRZHYHU6ROHQR7KHUDSH XWLFV,QFVKDOOEH
SURPSWO\QRWLILHGRIDQ\VXFKGLVFORVXUH

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
Soleno Therapeutics, Inc.   Page 2 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168306] OF ABBREVIATION S ................................ ................................ ......................... 16 
4.0 BACKGROU ND ................................ ................................ ................................ .............. 20 
4.1 Prader -Willi Syndrome  ................................ ................................ .......................... 20 
  
4.2.1  Mode o f Action  ................................ ................................ ..................... 21 
4.3 Nonclinical and Clinical Data  ................................ ................................ ................ 21 
  
  
  
  
  
  
[IP_ADDRESS]  Clinic al Safety and Efficacy Studies  ................................ .............. [ADDRESS_1168307]  ................................ ................................ ................................ ......... 26 
4.7 Population  ................................ ................................ ................................ .............. 26 
5.0 TRIAL OBJECTIVES ................................ ................................ ................................ .....26 
5.1 Primary  ................................ ................................ ................................ ................... 26 
5.2 Secondary  ................................ ................................ ................................ ............... 26 
  
6.0 TRIAL DESIGN ................................ ................................ ................................ ............... 27 
6.1 Study Endpoints  ................................ ................................ ................................ .....27 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 4 of 132 
Confidential Information   11 June 2019  6.1.1  Primary Stud y Endpoints  ................................ ................................ ......27 
6.1.2  Secondary Study Endpoints  ................................ ................................ ..27 
  
6.1.4  Safety  Endpoints ................................ ................................ .................... 28 
  
6.2 Study Design/Type  ................................ ................................ ................................ .29 
6.3 Randomizatio n ................................ ................................ ................................ .......29 
  
6.3.2  Additional Steps Taken to Minimize/Avoid Bias  ................................ .[ADDRESS_1168308] Withdrawal  ................................ ................................ ................................ 38 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168309] Compliance  ................................ ................................ ......41 
9.0 STUDY PROCEDURES  ................................ ................................ ................................ .41 
9.1 Description of Study Procedures and Assessments  ................................ ............... 42 
9.1.1  Informed Consent / Assent  ................................ ................................ ....42 
9.1.2  Medical History, Medications and Demographics  ................................ 42 
9.1.3  Physical Examination  ................................ ................................ ............ 43 
  
  
  
  
9.1.4  Vital Signs  ................................ ................................ ............................. 45 
9.1.5  Weight  ................................ ................................ ................................ ...45 
  
9.1.7  Height  ................................ ................................ ................................ ....46 
9.1.8  Electrocardiogram (E CG) ................................ ................................ .....47 
9.1.9  Laboratory Tests ................................ ................................ .................... 47 
[IP_ADDRESS]  Monitoring of Laboratory Results  ................................ ................. [ADDRESS_1168310]  ................................ ................................ ............ 51 
9.1.13  Enrollment  ................................ ................................ ............................. 51 
9.1.14  Randomization  ................................ ................................ ...................... 52 
9.1.15  Dual -Energy Absorptiometry (DXA)  ................................ ................... 52 
9.1.16  Clinical Global Impression Scales  ................................ ........................ 52 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 6 of 132 
Confidential Information   11 June 2019  [IP_ADDRESS]  Clinical Global Impression of Improvement (CGI -I) .................... 53 
9.1.17  Caregiver -Completed Questionnaires  ................................ ................... 53 
[IP_ADDRESS]  Hyperphagia Questionnaire - Clinical Trials (HQ -CT) ................. 53 
  
[IP_ADDRESS]  Caregiver Global Impression of Change (GI -C) ............................ 54 
 
 
  
 
  
  
  
  
  
  
  
9.1.18  Study Drug Dispensation  ................................ ................................ ......57 
9.1.19  Study Drug Administration  ................................ ................................ ...58 
9.1.20  Study Drug Accountability  ................................ ................................ ...58 
9.1.21  Adverse Events  ................................ ................................ ..................... 59 
9.1.22  Concomita nt Medications / Procedures  ................................ ................ 59 
  
9.2 Schedule of Events  ................................ ................................ ................................ .60 
  
10.0  ASSESSMENT OF EFFICA CY ................................ ................................ ..................... 63 
10.1  Efficacy Parameters  ................................ ................................ ............................... 63 
11.0  ASSESSMEN T OF SAFETY  ................................ ................................ .......................... 64 
11.1  Safety Parameters  ................................ ................................ ................................ ...64 
11.2  Definitions ................................ ................................ ................................ .............. 65 
11.2.1  Adverse Event  ................................ ................................ ....................... 65 
11.2.2  Suspected Adverse Reaction  ................................ ................................ .65 
11.2.3  Serious Adverse Event  ................................ ................................ .......... 65 
[IP_ADDRESS]  Hospi[INVESTIGATOR_840888]  ................................ ..65 
11.2.4  Unexpected Adverse Event  ................................ ................................ ...66 
11.2.5  Expected Adverse Events  ................................ ................................ ......66 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 7 of 132 
Confidential Information   11 June 2019  11.3  Adverse Event Assessment  ................................ ................................ .................... 66 
  
[IP_ADDRESS]  Adverse Event Severity ................................ ................................ ..68 
[IP_ADDRESS]  Adverse Event Relationship  ................................ ........................... 68 
[IP_ADDRESS]  Vital Signs, Physical Examination and Clinical Laboratory 
Adverse Events  ................................ ................................ .............. 69 
11.3.2  Serious Adverse Event Reporting  ................................ ......................... 69 
12.0  STATISTICAL PLAN  ................................ ................................ ................................ .....70 
  
  
  
  
  
  
12.3  Efficacy Analyses  ................................ ................................ ................................ ..71 
12.3.1  Primary Efficacy Analysis  ................................ ................................ ....71 
12.3.1 .1 Multiple Comparisons - Control of the Alpha Level  ..................... 72 
12.3.2  Secondary Efficacy Analyses  ................................ ................................ 72 
  
12.4  Subgroup Analyses  ................................ ................................ ................................ 73 
12.5  Safety Anal yses ................................ ................................ ................................ ......73 
12.5.1  Adverse Events  ................................ ................................ ..................... 73 
12.5.2  Clinical Laboratory Evaluations  ................................ ........................... 73 
  
12.5.4  ECG Parameters  ................................ ................................ .................... 74 
12.5.5  Vital  Signs  ................................ ................................ ............................. 74 
  
  
  
  
  
12.7  Termination Criteria ................................ ................................ ............................... 75 
12.8  Deviation Reporting  ................................ ................................ ............................... 75 
12.9  Interim Analysis  ................................ ................................ ................................ .....76 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168311] ACCESS TO SOU RCE DATA/DOCUMENTATI ON ................................ [ADDRESS_1168312] KEEPI[INVESTIGATOR_1645]  ................................ .......................... 77 
17.0  PUBLICATION PLAN  ................................ ................................ ................................ ...77 
18.0  REFERENCES  ................................ ................................ ................................ ................. 79 
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 9 of 132 
Confidential Information   11 June 2019  CHANGES FROM PREVIOU S VERSION  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 10 of 132 
Confidential Information   11 June 2019  2.0 STUDY SYNOPSIS  
Title of Study:  A Randomized, Double -Blind, Placebo -Controlled Study of Diazoxide 
Choline Controlled -Release Tablet (DCCR) in Patients with Prader -Willi 
Syndrome  
Sponsor:  Soleno Therapeutics, Inc.  
Phase of 
Development:  III 
Objectives:  Primary  
The primary objective of this study is to evaluate the effects of diazoxide 
choline controlled -release (DCCR) tablet compared to placebo on hyperphagia 
in PWS patients.  
 
Secondary  
The secondary objectives of this study are to evaluate changes in body fat  
mass , Clinical Global Impression of Improvement  (CGI -I), and Caregiver 
Global Impression of Change  (GI-C) with DCCR  compared to placebo in 
PWS patients.  
 
 
 
 
 
 
 
 
 
 
 
 
Study Design:  This is a multi -center, randomized, double -blind, placebo -controlled, parallel 
arm, phase III study comparing DCCR to placebo in approximately [ADDRESS_1168313] ‚Äôs expected duration of study participation is approximately 
105 days.  
 
   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 11 of 132 
Confidential Information   11 June 2019  Study  Design  
(cont) : For subject s who are continuing on into clinical study C602, the open -label, 
long-term, safety extension study, C601 Visit [ADDRESS_1168314] ‚Äôs weight.   
Study 
Population:  Patients with genetically -confirmed Prader -Willi syndrome.  
Screening 
Inclusion 
Criteria : Potential subject s must meet all of the following inclusion criteria to be 
enrolled:  
Provide voluntary, written informed consent (parent(s) / legal guardian(s) 
of subject ); provide voluntary, written assent ( subject s, as appropriate)  
Male and female subject s, [ADDRESS_1168315]  throughout the study a minimum of 
4 waking hours per day  
 
 
 
 
 
 
 
 
  
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 12 of 132 
Confidential Information   11 June 2019  Screening 
Inclusion 
Criteria  
(cont inued ):  
 
 
   
Screening 
Exclusion 
Criteria:  Potential subject s must not meet  any of the following exclusion criteria to be 
enrolled : 
  
Have participated in an interventional clinical study (i.e., investigational 
drug or device, approved drugs or device evaluated for unapproved use) 
within [ADDRESS_1168316]‚Äôs information or data into a non -interventional study 
and/or observational study (e.g., PATH for PWS) or PWS registry(ies) 
during the subject‚Äôs participation in this study    
 
  
  
  
 
 
  
 
 
  
 
 
 
  
 
 
  
  
 
 
  
 
 
  
 
 
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 13 of 132 
Confidential Information   11 June 2019  Screening 
Exclusion 
Criteria 
(continued):   
 
 
  
 Positive urine pregnancy test (in females of child -bearing potential)  
Females who are pregnant or breastfeeding, and/or plan to become 
pregnant or to breast -feed during or within 90 days after study 
participation  
 
 
 
 
 
 
 
 
Any other known disease and/or condition, which would prevent, in the 
opi[INVESTIGATOR_689], the subject  from completing all study visits 
and assessments required by [CONTACT_840897] C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 14 of 132 
Confidential Information   11 June 2019  Efficacy 
Evaluation:  
 Primary Endpoint  
‚Ä¢ Hyperphagia (H Q-CT) change from Baseline (Visit 2) to Visit  7 
Secondary Endpoints  
‚Ä¢ Body fat mass (DXA) change from Baseline to Visit 7  
‚Ä¢ Clinical Global Impression of Improvement at Visit 7  
‚Ä¢ Caregiver Global Impression of Change at Visit 7  
 
  
  
 
  
 
  
 
  
 
 
  
  
  
  
   
   
  
 
  
 
  
  
  
 
  
 
  
 
  
 
  
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 15 of 132 
Confidential Information   11 June 2019  Efficacy 
Evaluation  
(cont inued ):  
 
 
 
Safety 
Evaluation:  Safety Endpoints  
‚Ä¢ Adverse events  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168317] OF ABBREVIATION S 
Abbreviation or Term  Definition/Explanation  
AE Adverse Event  
AgRP  Agouti -Related Peptide  
ALT  Alanine aminotransferase  
ANCOVA  Analysis of Covariance  
  
   
ATP  Adenosine triphosphate  
  
C Celsius  
C-SSRS  Columbia Suicide Severity Rating Scale  
CFR  Code of Federal Regulations  
CGI-I Clinical Global Impression of Improvement  
CGI-S Clinical Global Impression of Severity  
CHI Congenital Hyperinsulinism  
Cmax  Maximum concentration  
cm Centimeters  
CMH  Cochran -Mantel -Haenszel  
CSR  Clinical Study Report  
CTCAE  Common Terminology Criteria for Adverse Events  
CYP  Cytochrome  P450  
DBC , DBC2 -P Developmental Behaviour Checklist , DBC Version [ADDRESS_1168318]  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
EDC  Electronic Data Capture  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 17 of 132 
Confidential Information   11 June 2019  Abbreviation or Term  Definition/Explanation  
eGFR  Estimated glomerular filtration rate  
EtOH  Ethanol  
EU European Union  
F Fahrenheit  
FDA  Food and Drug Administration  
FPG Fasting Plasma Glucose  
g Gram  
g/mol  Grams per mole  
GCP  Good Clinical Practice  
GGT  Gam ma-Glutamyl Transferase  
GI Gastrointestinal  
GI-C Global Impression of Change  
GI-S Global Impression of  Severity  
GLP  Good Laboratory Practices  
HbA1c  Hemoglobin A1c or glycated hemoglobin test  
HDL  High -Density Lipoprotein  
hERG  Human Ether-a-go-go Related Gene 
HFD  High -Fat Diet 
HOMA -IR Homeostatic Model Assessment of Insulin Resistance  
HQ-CT Hyperphagia Questionnaire for Clinical Trials  
HSP Hysterosalpi[INVESTIGATOR_840889]‚Äôs Brochure  
IC50 Half Maximal Inhibitory Concentration  
ICH International Conference on Harmonization  
ID Imprinting Defect  
IEC Independent Ethics Committee  
IGF-1 Insulin -Like Growth Factor  
IM Intramuscular  
IPA Isopropyl Alcohol  
INR International Normalized Ratio  
Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 18 of 132 
Confidential Information   11 June 2019  Abbreviation or Term  Definition/Explanation  
IRB Institutional Review Board  
ITT Intent -to-Treat  
IUD Intrauterine Device  
IV, i.v.  Intravenous  
IWRS  Interactive Web Response System  
K+ Potassium  
KATP ATP -Sensitive Potassium Channel  
kg Kilogram  
LDL  Low-Density Lipoprotein  
LFT Liver Function Tests  
MAGEL2  MAGE Family Member L2  
MCH  Mean Corpuscular Hemoglobin  
MCHC  Mean Corpuscular Hemoglobin Concentration  
MCV  Mean Corpuscular Volume  
MeCN  Acetonitrile  
MeOH  Methanol  
MEK  Methyl Ethyl Ketone  
mg Milligram  
min Minute  
MITT  Modified Intent -to-Treat  
mL Milliliter  
¬µM Micromolar  
Mm Millimeter  
mrem  Millirem  
msec  Millisecond  
m2 Meters Squared  
NPY  Neuropeptide Y  
OECD  Organisation for Economic Cooperation and Development  
P Placebo  
pH Hydrogen ion concentration  
Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 19 of 132 
Confidential Information   11 June 2019  Abbreviation or Term  Definition/Explanation  
PK Pharmacokinetic (s) 
PO Pes Os, By [CONTACT_840898] -Willi Syndrome  
PWSP  Prader -Willi Syndrome Profile  
QD Once -a-day 
QTcF  QT Interval corrected by [CONTACT_6550]‚Äôs Formula  
RBC  Red Blood Cell  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SD Standard Deviation  
SNORD  Small Nucleolar RNAs, C/D box  
TdP Torsades de Pointes  
TEAE  Treatment -Emergent Adverse Events  
ULN  Upper Limit of the Normal Range  
UPD  Uniparental Disomy  
US [LOCATION_002]  
V Visit  
WBC  White Blood Cell  
Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 20 of 132 
Confidential Information   11 June 2019  4.0 BACKGROUND  
Diazoxide choline , a new chemical entity,  is a benzothiadiazine that acts by [CONTACT_840899] -sensitive K+ channels (K ATP). It is the choline salt of diazoxide, which is currently 
used as a treatment of infants, children and adults with hyperinsulinemic hypoglycemia. 
Diazoxide choline, formulated as a once -a-day extended -release tablet or DCCR (diazoxide 
choline controlled -release) tablets, ha s been studied in over [ADDRESS_1168319] s 
with obesity, hypertriglyceridemia and Prader -Willi syndrome (PWS).      
4.1 Prader -Willi Syndrome  
Prader -Willi syndrome (PWS) is a complex neurobehavioral disorder, which is due to the 
absence of normally active, paternal ly expressed genes from the chromosome 15q 11-q13 
region .1, 2  PWS is an imprinted condition with 70 ‚Äì75% of the cases due to a de novo  deletion in 
the paternally inherited chromosome 15q11 -q13 region, 20 ‚Äì30% from maternal uniparental 
disomy o f chromosome 15 (UPD), and t he remaining 2 ‚Äì5% from either microdeletions or 
epi[INVESTIGATOR_840890] (i.e., imprinting defects; IDs).3, [ADDRESS_1168320] 350,000 to 400,000 indivi duals worldwide.1    
There are no currently -approved products to treat hyperphagia in patients with PWS.  Although 
growth hormone is approved in patients with PWS, it only addresses the short stature, and may 
reduce hypotonia , limit the accumulation of visceral fat , and reduce  cognitive impairmen t.5  A 
global patient survey conducted by [CONTACT_669591] -Willi Research ( n=779), found that 
96.5% of respondents rated reducing hunge r and 91.2% rated improving behavior around food as 
very important or most important symptom to be relieved by a new treatment.  Physical function 
and body composition symptoms for which a high pe rcentage of respondents indicated were very 
important or most important included:  improving metabolic health (reduces fat / increases 
muscle 92.9%) and the related symptom of improves activity and stamina (81.3%).  Behavioral 
and cognitive symptoms rated as very or most important were:  reduces obsessive /compulsive 
behavior (85.2%), improves intellect/development (84.6%), and reduces temper outburst severity 
and frequency (83.2%).6 
4.2 Investigational Agent  
  
 
   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 21 of 132 
Confidential Information   11 June 2019   
 
 
 
  
  
  
 
 
 
 
 
 
 
   
4.2.1 Mode of Action  
The lack of expression  of the SNOR D116 gene is associated with the overexpression of 
neuropeptide Y ( NPY ) a potent appetite stimulatory  neuro peptide.7  Additionally, in PWS, 
leptin‚Äôs reg ulatory control of hypothalamic neurons, particularly the NPY  / agouti -regulated 
peptide ( AgRP ) neurons, is diminished. Diazoxide choline appears to be effective in the 
treatment of the resulting hyperphagia by [CONTACT_840900] K ATP channels in these dysregulated 
neurons, there by [CONTACT_840901]. This leads to reduced  secret ion of 
NPY  by [CONTACT_840902] , resulting in decreased hyperphagia.   
4.3 Nonclinical and Clinical Data  
Summaries of the studies in this section are included in the Investigator‚Äôs Brochure for DCCR.   
   
  
 
     
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 22 of 132 
Confidential Information   11 June 2019   
  
  
 
 
 
  
  
  
  
 
   
  
 
 
 
 
   
 
 
 
 
 
   
  
 
   
 
 
 
  
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 23 of 132 
Confidential Information   11 June 2019   
 
 
 
   
 
 
   
 
 
 
 
 
4.3.2 Summary of Clinical Data  
 
 
  
  
 
 
 
 
 
 
 
  
[IP_ADDRESS]  Clinical Safety and Efficacy Studies  
Clinical study PC025 in PWS was conducted using DCCR.  This single -center, randomized 
withdrawal study consisted of [ADDRESS_1168321]  who showed  
 would be designated a Responder, 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168322] s treated with DCCR in  this clinical study showed clinically relevant, statistically 
significant and dose dependent improvements in hyperphagi a from Baseline to Day 69  (open -
label phase) .   
 
 
 
 
 
 
 
 
 
  
The adverse events associated with DCCR treatment and deemed related to DCCR by [CONTACT_840903]: peripheral edema, glucose 
tolerance impaired, and hyperglycemia.   
In all of the studies wit h DCCR completed  to date, t wo serio us adverse events (SAEs) have  been 
reported  (neither of which were deemed to be related to DCCR) : a case of pneumonia  and an 
overnight hospi[INVESTIGATOR_58170] a PWS subject  with poorly controlled psychiatric disease. Adverse 
events (AE) reported in these studies were typi[INVESTIGATOR_46544], self -limiting 
and were consistent with the existing diazoxide product labels and the results of previously 
published cli nical studies and case reports. DCCR  
 was well tolerated.  
The available clinical data with DCCR as well as the nonclinical data with diazoxide choline and 
diazoxide indicate that DCCR could be used to treat  multiple aspects of PWS including the 
characteristic hyperphagia , aggressive behaviors,  and accumulation of excess b ody fat.  
  
 
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 25 of 132 
Confidential Information   11 June 2019   
  
 
 
 
   
 
 
 
 
 
 
   
 
 
 
 
4.5 Dose Selection and Study Duration Ratio nale 
4.5.1 Dose Selection Rationale  
 
 
 
 
 
 
 
 
   
 
 
 
 
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168323], and according to Good Clinical Practice standards.  No change to the protocol 
will be implemented without the prior review and approval of the IRB /IEC  except where it may 
be necessary to eliminate an immediate hazard to a research subject .  In such case, the change 
will be reported to the Sponsor and IRB/IEC  as soon as possible.  
4.[ADDRESS_1168324] of patients with genetically -confirmed Prader -Willi syndrome 
(PWS).  
5.0 TRIA L OBJECTIVES  
5.1 Primary  
The primary objective of this study is to evaluate the effects of diazoxide choline controlled -
release (DCCR) tablet compared to placebo on hyperp hagia in PWS patients.  
5.2 Secondary  
The secondary objectives of this study are to evaluate changes in  body fat  mass , Clinical Global 
Impression of Improvement  (CGI -I), and Caregiver Global Impression of Change (GI-C) with 
DCCR  compared to placebo in PWS patients.  
5.3 Additional Objectives  
 
 
 
 
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 27 of 132 
Confidential Information   11 June 2019  6.0 TRIAL DESIGN  
6.1 Study Endpoints  
6.1.1 Primary Study Endpoints  
‚Ä¢ Hyperphagia (HQ -CT) change from Baseline (Visit 2) to Visit  7 
6.1.2 Secondary Study Endpoints  
The following secondary endpoints , in order,  are: 
‚Ä¢ Body fat mass (DXA) change from Baseline to Visit 7  
‚Ä¢ Clinical Global Impression of Improvement at Visit 7  
‚Ä¢ Caregiver Global Impression of Change at Visit 7  
6.1.3 Additional Study Endpoints  
  
  
 
  
 
  
 
 
  
  
  
  
   
   
  
  
  
  
  
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 28 of 132 
Confidential Information   11 June 2019    
 
  
 
  
 
  
 
  
 
  
 
6.1.4 Safety  Endpoints  
‚Ä¢ Adverse events  
  
  
  
  
  
  
  
  
  
  
   
  
  
  
  
  
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 29 of 132 
Confidential Information   11 June 2019     
  
6.2 Study Design/Type  
This is a multi -center, randomized, double -blind, placebo -controlled, parallel arm , phase III  
study comparing DCCR to placebo in approximately [ADDRESS_1168325] s with hyperphagia. This 
study will be conducted at approximately 3 0 sites globally .  
 
Figure  1: Study Design Schematic  
 
6.3 Randomization  
 
 
 
The randomization code will be generated and maintained by [CONTACT_840904],  Soleno Therapeutics, Inc. (Soleno) , and those related to the  day-to-day conduct of the 
study and/or the management of the study . 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 30 of 132 
Confidential Information   11 June 2019  6.3.1 Blinding  
 
 
  
 
 
 
 
 
Study drug will be blinded. Placebo tablets matching the size, shape, and color of the respective 
DCCR tablet strengths will be used.  
6.3.2 Additional Steps Taken to Minimize/Avoid Bias  
  
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168326] of the study and/or  the management of the 
study .   
In order to eliminate an immediate risk to  a subject , Investigators  will be able to obtain a specific 
subject ‚Äôs treatment group assignment.   
6.[ADDRESS_1168327] s will be randomized to one of two study treatments, diazoxide choline controlled -release 
(DCCR) or placebo.  Diazoxide choline is formulated into an extended -release tablet .   
  Placebo tablets matching the size, shape, and 
color of the respective DCCR tablet strengths , but not containing any diazoxide choline,  will be 
used.   
6.5.2 Packaging and Labeling  
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 32 of 132 
Confidential Information   11 June 2019  The Interactive Web Response System (IWRS) will indicate which cards will be assigned to each 
subject .  
6.5.[ADDRESS_1168328] be stored, handled, 
and administered in accordance with this protocol, the Investigator‚Äôs Brochure and labeling, as 
well as all applicable laws, regulations, and institution requirements.   
6.[ADDRESS_1168329] ‚Äôs expected duration of study participation is approximately  105 days; visit windows 
are described in Section 9.0.  
  
 
 
 
 
  For subject s who are continuing on into clinical study 
C602, Visit [ADDRESS_1168330] 
(DSMB ) will minimally review unblinded safety data twice  during the study : 
  
  
  
 
Additional  unblinded safety data reviews and/or  ad hoc reviews of unblinded safety data by [CONTACT_840905] (i.e., similar CTCAE Grade 3 or higher 
suspected adverse reactions occurring in excess in the DCCR group compared to placebo)  may 
be requested at the discretion of the DSMB.  
Based on the DMSB‚Äôs review of these unblinded da ta, study discontinuation reasons may 
include:    

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 33 of 132 
Confidential Information   11 June 2019  ‚Ä¢ The sponsor determines that it is unsafe to continue because of an unexpected safety signal 
not otherwise clinically anticipated in randomized subjects without relevant medical history  
‚Ä¢ Significant i mbalance in rate of serious, unexpected adverse reactions that , independent of 
study drug,  are not clinically anticipated in subjects randomized to DCCR v ersus placebo in 
subjects without relevant medical history  
‚Ä¢ Significant i mbalance in rate of serious adverse rea ctions that , independent of study drug,  are 
not clinically anticipated in subjects randomized to DCCR v ersus placebo in subjects without 
relevant medical history  
 
 
   
 
  
6.[ADDRESS_1168331] . 
 
 
 
 
 
 
 
 
 
 
 
6.9 Data Identification  
 
 
 
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 34 of 132 
Confidential Information   11 June 2019   
    
 
 
 
 
 
 
   
Data that are entered directly into an electronic medium (e.g., EDC, tablet, etc.) together with the 
metadata, are considered e Source data and are kept together as an electron ic record (eSource 
document) for capture, transmission and/or storage . 
 
 
 
 
 
   
 
 
 
 
 
  
 
   
 
 
 
 
7.[ADDRESS_1168332]  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 35 of 132 
Confidential Information   11 June 2019  and/or caregiver provide will be used to determine eligibility at the Screening  Visit (Visit  1). If 
the subject  does not meet these criteria, he/she will be considered a screen failure. The 
subject /caregiver must not be informed of the reason for failure to meet the screening criteria  
until the study is completed . 
7.1.[ADDRESS_1168333] meet all of the following inclusion criteria to be enro lled: 
Provide voluntary, written informed consent (parent (s) / legal guardian (s) of subject ); provide 
voluntary, written assent ( subject s, as appropriate)  
 
Genetically -confirmed Prader -Willi syndrome . If confirmation by a method other than 
methylation analysis, subject  and caregiver consent to methylation analysis.  
 
 In a stable care setting for at least [ADDRESS_1168334] not meet any of the following exclusio n criteria to be enrolled : 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168335] participated in an interventional clinical study (i.e., investigational drug or device, 
approved drugs or device evaluated for unapproved use) within 60 days  prior to Visit 1  
 
 
 
 
  
  
  
 
 
 
 
  
 
 
  
 
  
  
 
  
 
 
  
 
 
 
 
 
 
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168336] (in females of child -bearing potential)  
 Females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast -feed 
during or within 90 days after study participation  
 
 
 
 
 
 
 Any other known disease and/or condition, which would prevent, in the opi[INVESTIGATOR_684], the subject  from completing all study visits and assessments required by [CONTACT_840906] C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168337] s and/or parent (s) / legal guardian(s) are free to withdraw consent and discontinue 
participation in the study at any time without prejudice to further treatment. Female subject s who 
become pregnant will be withdrawn  from the study .   
     
 
    
  
 
  
 
   
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168338] will be packaged for home administration.  
  
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168339]  will be maintained on that dose for the remainder of 
the treatment period.  
   
 
 
 
 
 
  
 
 
 
 
8.6 Medication  
All concomitant medications (i.e., pharmaceuticals, biologics, herbal preparation, homeopat hy, 
nutraceuticals, or procedures [ e.g., acupuncture, vagal stimulation] ) will be approved by [CONTACT_840907] 2.   Once the subject  is randomized,  any new , chronic,  
concomitant medication  given to the subject  should be discussed with the Medical Monitor .  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 41 of 132 
Confidential Information   11 June 2019  8.6.1 Prohibited Medications  and Procedure s 
The following medications are not permitted  within 3 months  prior to Screening (Visit 1) and 
during the study : 
‚Ä¢ Anti-obesity medications or other medications (including he rbal preparations, over -the- 
counter products) or procedures for weight reduction  
  
 
 
  
 
 
  
  
 
‚Ä¢ Any investigational drugs or  devices  
 
 
 
8.[ADDRESS_1168340] ‚Äôs compliance with the study drug  administration.    
 
   
9.0 STUDY PROCEDURES  
The following sections describe the procedures and assessments that will be performed during 
the study.  The Schedule of Events, located in Section 9.2, indicates the frequency of these 
procedures and assessments .   
  
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 42 of 132 
Confidential Information   11 June 2019   
 
 
 
    
9.1 Description of Study Procedures and Assessments  
9.1.1 Informed Consent / Assent  
At the beginning of the Screening Visit, potential par ticipants  and their parents(s) or legal 
guardian(s) will be given an IRB /IEC -approved informed consent form  and an IRB /IEC -
approved assent form by a member of the study site personnel (i.e., study coordinator, 
Investigator, or other study site personnel).  Parent(s) / legal guardian(s) of p otential participants  
and potential participants  will be provided time to read the consent  and assent forms  as well as 
the opportunity to ask questions and have their questions answered prior to the initiation of any 
study-specific assessments.  Parents / legal guardians  of subject s must voluntarily provide 
written informed consent  and subject s must voluntarily provide written consent or assent , as 
applicable,  before any study -related assessment s are performed.  Once signed by [CONTACT_7071](s) / 
legal guardian(s) , subject  and the study site personnel performing the consent process, a copy of 
the consent form and assent form , as applicable,  will be given to the parent(s) / legal guardian(s).  
The original forms will be stored in the study site‚Äôs files.  The subject ‚Äôs medical records/source 
documents must include documentation that written informed consent  and written assent  was 
obtained from parent(s) / legal guardian(s)  and subject , and that the parent(s) / legal guardian(s) 
of subject  received copi[INVESTIGATOR_836084], fully -executed informed consent form  and assent form .  
In the event that the caregiver is not the parent or legal guardian, the source documents will need 
to include documentation that the  caregiver was designated  by [CONTACT_7071] / legal guardian  to 
complete questionnaires for the subject . All of the applicable eligibility criteria for the designated 
caregiver must be met.     
9.1.[ADDRESS_1168341] ‚Äôs relevant medical history and any 
medication and supplements (e.g., homeopathy, natural health products, etc.) the subject  is 
currently taking  or ha s taken,  or procedures performed  within [ADDRESS_1168342] ‚Äôs demographic information  (age, gender, race, and 
ethnicity) will be collected.  Potential fertility should be assessed .  Subject s who are considered 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 43 of 132 
Confidential Information   11 June 2019  potentially fertile should receive contraception instruction as deemed necessary by [CONTACT_3786]. Refer to Appendix  1 for additional information.   
 
 
 
 
9.1.3 Physical Examination  
A full physical exam ination (exam) , including all major bod y systems , will be performed at each 
visit 
 
 
 
 
 
 
   
Any conditions or sympto ms reported after the subject  is enrolled at the Screening Visit  will be 
recorded as an AE on the AE eCRF.  This includes new events , conditions , disease -related signs 
or symptoms  that have worsened in severity or increased in frequency , and any event or finding 
that the Investigator feels is clinically significant.   
  
 
 
 
 
 
    
  
 
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 44 of 132 
Confidential Information   11 June 2019    
 
   
  
  
  
  
  
 
  
 
   
  
 
 
 
    
 
  
 
 
 
 
   
 
 
  
 
 
  
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 45 of 132 
Confidential Information   11 June 2019   
     
  
 
 
 
   
  
   
  
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
9.1.4 Vital Signs  
Vital signs will be measured at every visit  
  Vital signs include 
temperature, systolic and diastolic blood pressure, pulse rate, and respi[INVESTIGATOR_1516] .   
 
 
    
9.1.5 Weig ht 
Body weight will be measured at every visit  
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
Soleno Therapeutics, Inc.  Page 46 of 132 
Confidential Information  11 June 2019   
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
9.1.7 Height  
Height will be measured at the Baseline Visit  and the End of Study 
Visit  
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
Soleno Therapeutics, Inc.  Page 47 of 132 
Confidential Information  11 June 2019   
 
9.1.8 Electrocardiogram (ECG)  
A 12 -lead electrocardiogram (ECG) will be performed at the Screening Visit (Visit 1) , Visit 6  
and the End of Study Visit (Visit 7).  It is not necessary for the subject to be fasting for  any 
ECGs .   
 
 
.   
The ECG performed at the Screening Visit will serve as the baseline ECG to evaluate changes.  
Nurses or investigators experienced in performing ECGs will perform the ECGs.   
 
 
  
  
A trained cardiologist at the study site will review the ECG output and provide an assessment of 
the interval s, segments , abnormalities of T -wave or U -wave  morphology , and a diagnostic 
statement to the investigator.   
9.1.[ADDRESS_1168343] overnight (at least 8 , but preferably 10 -12 hours  
prior to  the collection of their  blood ).  They must not have anything to eat or drink, except water .  
The following blood tests will be performed on blood collected, prior to study drug  
administration  during the study at the Visits as defined in the Schedule of Events (Section 9.2).    
‚Ä¢Fasting Plasma Glucose
‚Ä¢Fasting Plasma Insulin
‚Ä¢HbA1c
‚Ä¢IGF-1
‚Ä¢Chemistry Panel

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168344] Bilirubin (calculation)  
- Alka line Phosphatase  
- Alanine Transaminase (ALT)  
- Aspartate Aminotransferase (AST)  
- Gamma -Glutamyl Transferase (GGT)   
- Magnesium  
- Chloride  - Calcium  
- Phosphorus  
- Total Protein  
- Albumin  
- Globulin (calculation)  
- Uric Acid  
- Creatine Kinase  
- Blood Urea Nitrogen  - Creatinine  
- Estimated 
glomerular 
filtration rate 
(calculated -
screening only)  
- Sodium  
- Potassium  
- Bicarbonate  
‚Ä¢ Hema tology Panel   
- Hemoglobin  
- Hematocrit  
- WBC  
- RBC  
- RBC morphology  - MCV  
- MCH  
- MCHC  
- Platelets   
- Neutrophils (abs, %)  - Lymphocytes (abs, %)  
- Monocytes (abs, %)  
- Basophils (abs, %)  
- Eosinophils (abs, %)  
‚Ä¢ Coagulation  Panel   
- APTT  - PT - INR 
‚Ä¢ Lipid Panel  
- Triglycerides  
- Total C holesterol  
- HDL Cholesterol  
- Non-HDL Cholesterol  
- LDL Cholesterol   
‚Ä¢ Urinalysis  
- Color and clarity  
- Specific gravity  
- pH 
- Protein  - Glucose  
- Ketones  
- Bilirubin  
- Urobilirubin  - Blood  
- Nitrite  
- Leukocyte esterase  
Microscopic  
  
  
   
    
Instructions on sample collection, processing, storage, packaging and shippi[INVESTIGATOR_840891].   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 49 of 132 
Confidential Information   11 June 2019  [IP_ADDRESS]  Monitoring of Laboratory Results  
Each subject ‚Äôs laboratory reports will be sent by [CONTACT_840908], who 
will assess the results for clinical significance.   
 
 
 
   
  
 
 
 
 
 
  
 
 
 
 
 
 
  
   
   
    
    
   
   
 
 
 
  
 
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 50 of 132 
Confidential Information   11 June 2019  ‚Ä¢  
 
 
 
 
 
  
 
 
  
 
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168345] s will be assigned a unique identification number .    

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168346] s who meet the eligibility criteria for randomization will be eligible for 
randomization into the study.   
9.1.15  Dual -Energy Absorptiometry ( DXA ) 
 dual-energy 
absorptiometry (DXA) will be used to  measure the subject s‚Äô bo dy composition .  Whole body  
(with head)  scans will be performed . Reports should include a breakdown of the fol lowing 
regions: left arm, right arm, trunk, left leg, right leg, and head. Each region should  be evaluated 
for body fat mass (g), lean body mass (g), total mass (g) and percent (%) body fat.  If the DXA 
scan report  includes Region % fat and Tissue %fat, th en the Region % fat should be recorded on 
the eCRF for percent body fat.    
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
9.1.16  Clinical Global Impression Scales  
Two Clinical Global Impression (CGI) scales are completed by [CONTACT_737]:  CGI of Severity 
and CGI of Improvement.  For the these scales , it is important for the Investigator to establish the 
presence of re levant symptoms, their frequency, intensity or severity and their effect on the 
major areas of the subject ‚Äôs life such as work, home, school and relationships . 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 53 of 132 
Confidential Information   11 June 2019    
 
 
 
 
 
    
 
  
[IP_ADDRESS]  Clinical Global Impression of Improvement (CGI -I)  
The Clinical Global Impression of Improvement (CGI -I) for Improvement is a single statement 
designed to assess the Investigator‚Äôs overall perception of change in the subject ‚Äôs condition 
across the course of the clinical trial.  The Investigator provides a response to ‚ÄúCompared to the 
subject ‚Äôs condition at enrollment, the subject ‚Äôs condition is:‚Äù by [CONTACT_840909] ‚Äôs behavior 
using a 7 -point response scale: Very much improved, Much improved, Minimally improved, No 
change, Minimally worse, Much worse, and  Very much worse. The Investigator should only take 
into account the subject‚Äôs PWS condition.  
  
9.1.17  Caregiver -Completed Questionnaires  
Caregiver questionnaires and interviews should be administered in a relaxed, informal setting.  
 
 
 
 
  The caregiver should consider all environments and situations  including, but not 
limited to, school, work, and outside activities .  In addition, nights  and weekends should be 
considered.   
 
 
[IP_ADDRESS]  Hyperphagia Questionnaire - Clinical Trials (HQ -CT) 
Hyperphagia -related behaviors will be assessed by [CONTACT_840910] (HQ -CT), an instrument designed to measure symptoms of food related 
preoccupations and behaviors that will be completed by [CONTACT_840911] -CT 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 54 of 132 
Confidential Information   11 June 2019  consists of nine items with responses ranging from 0 ‚Äì4 units each (possible total score range: 
0‚àí36).   
  
 
   
 
     
  
 
 
 
 
   
 
  
[IP_ADDRESS]  Caregiver Global Impression of Change (GI -C) 
The Caregiver Global Impression of Chan ge (GI -C) is a single statement designed to assess the 
caregiver‚Äôs overall perception of change in the subject  across the  course of the clinical trial.  The 
caregiver provides a response to ‚ÄúPlease choose the response below that best describes the 
overall change in the person‚Äôs PWS since they started taking the study medication‚Äù using a 7-
point graded response scale: Very m uch better, Moderately better, A little better, No change , A 
little wo rse, Moderately worse, and Very m uch worse.    
 
 
  
 
 
 
 
 
 
 
   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 55 of 132 
Confidential Information   11 June 2019   
 
  
  
 
 
 
 
 
 
 
 
  
  
 
 
   
 
    
  
  
  
  
  
  
 
 
 
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 56 of 132 
Confidential Information   11 June 2019   
  
  
 
 
  
 
  
 
 
   
 
 
 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
   
   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 57 of 132 
Confidential Information   11 June 2019    
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
   
   
 
 
 
  
 
 
 
 
   
9.1.18  Study Drug Dispensation  
 
 
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168347]  will be provided a sufficient supply of study drug plus some overage for daily 
administration of the assigned dose until the subsequent visit.    
 
9.1.19  Study Drug  Administration  
The study drug  is to be administered by [CONTACT_1966] (PO) once  daily  in the morning at approximately 
the same time, with water  or another beverage .  
  
 
 
  
 
 
 
  
 
 
   
 
 
 
 
  
9.1.20  Study Drug  Accountability  
At Screening (Visit 1) , the caregiver will be instructed on how to the record the date and time 
when the  study drug  is taken on the study medication  cards.  At each subsequent visit, a member 
of the study site personnel will review with the caregiver the recorded information  on the study 
medication  cards  then document dosing compliance and note discrepancies, if any, in the source 
documents and on the appropriate eCRF.  
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168348] s will be monitored for safety from the time they are enrolled at the Screening Visit 
(Visit  1) until the End of Study Visit  (Visit 7).  Any conditions or symptoms reported will be 
recorded as an AE in the subject ‚Äôs source documents and on the AE eCRF page.  Subject s who 
have an ongoing AE related to study drug will be followed until resolution or stabilization of the 
event.  
 
 
 
 
 
   
 
 
 
  
9.1.22  Concomitant Medications / Procedures  
Medications taken and procedures performed,  will be 
recorded in the subject ‚Äôs source document  
 
 
 
 
 
 
 
 
 
  
 
 
 
   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 60 of 132 
Confidential Information   11 June 2019  9.2 Schedule of Events  
Visit Number  1 2  
   5  6  7‚Ä†, 
End of 
Study Screening  Pre-
Rand  Post-
Rand  
Day  -14 0 14 28 42 56 91 
Week  -2 0 2 4 6 8 13 
Informed Consent, Assent  X        
Demography  X        
Medical History  X X*       
Screening Inclusion/ Exclusion Criteria Review  X        
Enrollment  X        
Randomization  Inclusion/ Exclusion Criteria Review   X       
Randomization   X      
Physical Examination,  
 
 Vital Signs, 
Weight, Waist Circumference  X X**  X1 X1 X1 X1 X** 
Height   X      X 
         
         
Urine Pregnancy Test*** X X  X X X X X 
         
          
Hematology Panel including PT, APTT and INR, 
Chemistry Panel, LFTs  X X  X X X X X 
HbA1c  X       X 
Lipid Panel   X   X  X X 
IGF-1  X      X 
         
Urinalysis   X   X  X X 
         
         
DXA Scan   X     X 
Hyperphagia Questionnaire (HQ -CT) X X   X  X X 
         
 
         
CGI-I, 
   X#  X  X X 
         
         
         
Study Drug Dispensation  X  X X X X X  
Study Drug Accountability   X  X X X X X 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 61 of 132 
Confidential Information   11 June 2019  Visit Number  1 2  
   5  6  7‚Ä†, 
End of 
Study Screening  Pre-
Rand  Post-
Rand  
Day  -14 0 14 28 42 56 91 
Week  -2 0 2 4 6 8 13 
Study Drug Administration## X  X X X X X  
Adverse Events  X X X X X X X X 
Concomitant Medications  X X X X X X X X 
‚Ä† Visit [ADDRESS_1168349] s who enroll in Study 
C602.  
  
   
  
   
  
  
‚Ä†‚Ä† ECG performed at the Screening Visit will be used as the baseline ECG to evaluate changes.  
  
  
  
 
  
  
  
  
Full physical examination to be conducted if needed.   
***  For females of child -bearing potential only.   A positive urine pregnancy test must be confirmed 
by [CONTACT_142668].  
  
  
  
  
 
   
## At each visit, after t he necessary procedures have been completed, the  assigned dose of DCCR or 
placebo  will be taken in the clinic  with water  or other beverage . All other doses will be taken 
daily in the morning as described in Section 8.1 
  
 
 
 
  
   
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 62 of 132 
Confidential Information   11 June 2019    
 
 
 
   
 
      
      
      
      
      
      
  
     
      
      
      
   
     
      
   
  
 
 
 
 
 
   
 
 
 
 
 
 
   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 63 of 132 
Confidential Information   11 June 2019   
 
 
 
 
 
 
 
 
 
 
  
10.0 ASSESSMENT O F EFFICACY  
10.1 Efficacy Parameters  
The efficacy parameters that will be assessed in this study are: 
‚Ä¢ HQ-CT score 
‚Ä¢ Body fat mass  (DXA ) 
‚Ä¢ Clinical Global Impression of Improvement  
  
‚Ä¢ Caregiver Global Impression of Change   
  
  
  
  
  
  
  
  
  
  
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 64 of 132 
Confidential Information   11 June 2019    
  
  
  
  
   
  
  
   
  
 
11.0 ASSESSMENT O F SAFETY  
11.1 Safety Parameters  
The safety parameters that will be assessed in this study are:   
‚Ä¢ Adverse events  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 65 of 132 
Confidential Information   11 June 2019  11.2 Definitions  
The following definitions, developed in accordance with the International Committee on 
Harmonization (ICH) Clinical Safety Data Management Guidance for Industry, E2A, 21  CFR 
Part 312.32 , and EU Directive 2005/28/EC and Regulation 536/2014  will be used for the purpose 
of identifying AEs in this clinical study.   
11.2.1  Adverse Event  
An adverse even t (AE) is any untoward medical occurrence in a clinical investigation patient, 
administered a pharmaceutical product which does not necessarily have to have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding, for example), symptom, or increase in severity or 
frequency of a pre -existing abnormality, temporally associated with the use of a medicinal 
(investigational) product, whether or not considered related to the medicinal  (investigational) 
product.   
11.2.[ADDRESS_1168350] of the adverse e vents 
that are evaluated by [CONTACT_840912].   
11.2.3  Serious Adverse Event  
A serious adverse event (SAE) is any adverse experience occurring after enrollment at any dose 
that results in any of the follo wing outcomes:  death, life-threatening (at the time of the event) , 
hospi[INVESTIGATOR_1081] , a persistent or significant incapacity or 
substantial disruption of the ability to conduct normal life functions , or a congenita l 
anomaly/birth defect (in an offspring)  
Medically significant  events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_12475], based upon appropriate medical judgment, the 
event may jeopardize the subject  and/or the subject  may require medical or surgical intervention 
to prevent one of the outcomes listed in this definition.   
[IP_ADDRESS]  Hospi[INVESTIGATOR_840892].   
Hospi[INVESTIGATOR_840893]: short -term administrative hospit alization for procedures, tests 
Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 66 of 132 
Confidential Information   11 June 2019  or treatments of conditions that would not otherwise constitute an SAE, or elective 
hospi[INVESTIGATOR_602].  
11.2.4  Unexpected Adverse Event  
Any adverse event that is not listed in the Reference Safety Information section  in the  
Investiga tor‚Äôs Brochure or is not listed at the same specificity or severity that has been observed  
previously .   
11.2.[ADDRESS_1168351] 10% of subjects include peripheral edema and 
headache.  AEs reported in 2 -9% of subjects include decreased appetite, palpi[INVESTIGATOR_814], 
hyperglycemia, fluid retention, dizziness, chest pain, fatigue, tachycardia, nausea, hirsutism, 
abdominal distensi on, and arthralgia.  
11.[ADDRESS_1168352] a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding, for example), symptom, or d isease temporally 
associated with the use of a medicinal product, whether or not related to the medicinal product.   
AEs may include increases in intensity or frequency of conditions or diseases that were pre -
existing prior to study participation.  An e xample might include a subject  in whom routine 
headaches become more severe or begin to occur more frequently.   
Medical or surgical procedures are not in and of themselves considered AEs, but if a condition or 
disease led to the procedure, the condition or d isease would be considered an AE unless it was 
present prior to entering the study and did not worsen after entering the study.   
When possible, AEs will be graded according to CTCAE criteria ( CTCAE , Version 5.0 , which 
can be found online at  https://evs.nci.nih.gov/ftp1/CTCAE ).  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168353] their 
signs/symptoms graded according to CTCAE criteria. Increases in CTCAE grading from 
baseline co nditions (e.g., Grade 1 to Grade 2) will be considered adverse events.   
A non -serious  AE is any AE that does not meet the definition of a serious adverse event.   
11.3.1  Performing AE Assessments  
 
   
  
  
  
  
  
  
  
  
 
  
   
 
 
 
  
 
 
 
 
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 68 of 132 
Confidential Information   11 June 2019  [IP_ADDRESS]  Adverse Event Severity  
AEs will be assessed for severity (intensity) according to the clinical description prov ided in the 
CTCAE  Version 5.0  (Grade 1, Grade 2, Grade 3, Grade 4, or Grade 5).  If an AE cannot be 
classified using CTCAE terminology, severity will be assessed using the following definitions 
listed in Table 8. 
Table 8: Adverse Event Severity  
Grade 1  Mild  Asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated.  
Grade 2  Moderate  Minimal, local, or noninvasive intervention indicated; limiting age -
appropriate instrumental activities of daily living.1  
Grade 3  Severe  Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; 
disabling; limited self -care activities of daily living.2 
Grade 4  Life-threatening  Life-threatening consequences; urgent intervention indicated.  
Grade 5  Death  Death related to the AE.  
1 Examples of instrumental activities of daily living includ e: Watching television, using a computer, 
playing video games, attending school, playing outside, using the telephone, etc.  
2 Examples of self -care activities of daily living are: bathing, dressing and undressing, feeding self, using 
the toilet, taking medic ations, etc.  
 
[IP_ADDRESS]  Adverse Event Relationship  
For each AE, the Investigator is required to assess the causal relationship (relatedness) between 
the administration of the study drug and the occurrence of the AE.  The Investigator should use 
his or her clinical judgment and the following definitions to determine relatedness.  
‚Ä¢ Not Related:  The AE is not related if exposure to the study drug has not occurred, or the 
occurrence of the AE is not reasonably related in time, or the AE is considered unlikely to be 
related to use of the study drug, i.e., there are no facts (evidence) or arguments to suggest a 
causal relationship  
‚Ä¢ Unlikely Related:   The AE is more or most likely explained by [CONTACT_840913] 
‚Ä¢ Possibly  Related : The administration of th e study drug and AE are considered reasonably 
related in time and the AE could be explained by [CONTACT_840914] C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 69 of 132 
Confidential Information   11 June 2019  ‚Ä¢ Probably  Related : Exposure to the study drug and AE are reasonably related in time and 
the study drug is more likely  than other causes to be responsible for the AE, or is the most 
likely cause of the AE.  
 
[IP_ADDRESS]  Vital Signs, Physical Examination and Clinical Laboratory Adverse Events  
Laboratory abnormalities and changes in vital signs or physical examination/findings are 
consi dered AEs only if they are determined to be clinically significant by [CONTACT_941] I nvestigator , result 
in withdrawal from the study, necessitate therapeutic intervention, or for some other reason the 
Investigator  considers them clinically important.  However, if a ny of these changes in laboratory, 
vital signs or physical examinations is attributable to a new disease or condition or a worsening 
of a condition pre -existing study enrollment, the disease or condition itself shall be the reported 
AE, not the change in l aboratory, vital sign or physical examination.  
11.3.[ADDRESS_1168354]  is enrolled at Screening through the End of S tudy Visit are 
reportable within 24  hours.   
The procedure for reporting an SAE is as follows:  
‚Ä¢ Within [ADDRESS_1168355] Soleno by [CONTACT_840915].  
‚Ä¢ The initial report should include al l information known at the time of the report  (additional 
information can be reported as discovered).  Initial reporting should not be delayed in order 
to obtain resolution or follow -up information.  
‚Ä¢ The site will fax an SAE report, or similar form, which  includes the following information, as 
available:  
‚Äì Study subject number  
‚Äì Basic demographic information (age, gender, weight)  
‚Äì Relationship to study drug  
‚Äì The outcomes attributed to the event (death, life -threatening, hospi[INVESTIGATOR_059] [new or 
prolonged], disab ility, congenital anomaly, required medical intervention to prevent 
permanent impairment/damage, etc.)  
‚Äì The onset date and severity of the event  
‚Äì A brief description of the event including frequency and severity of symptoms leading to 
diagnosis  
Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 70 of 132 
Confidential Information   11 June 2019  ‚Äì A list of rel evant test results and lab data  
‚Äì Any other relevant history  
‚Äì Date of study drug administration  
‚Äì Whether the study drug was discontinued prematurely  
‚Äì Investigator‚Äôs assessment of causality  
The completed SAE report should be sent electronically as soon as possible (within 24  hours) to:  
 
 
 
The Medical Monitor or another representative  or designee  of Soleno may contact [CONTACT_840916] a dditional information regarding the event or to confirm information.  All 
SAEs will be entered on the AE eCRF.  The same nomenclature should be used on both the SAE 
report and the AE eCRF.   
The Investigator is responsible for the complete and timely repor ting of all SAEs to Soleno, 
following up on resolution of the SAE, and expeditiously and simultaneously notifying the 
responsible IRB /IEC  of the occurrence and details of the event according to institutional standard 
procedures.  In the event there is a qu estion as to whether the experience is serious, the event 
should be reported.  
12.[ADDRESS_1168356] s.  
12.1 Sample Size Justification  
 
   
 
 
 
    
 
 
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168357] s who are randomized to the wrong hyperphagia score gr oup or 
growth hormone status will be analyzed in the stratum t hey belong in (vs. stratum randomized to 
if there are errors).   
12.3.1  Primary Efficacy Analysis  
The primary endpoint (change from Baseline to Visit [ADDRESS_1168358] score) will be analyzed 
using a linear mixed model for repeated measurements in the ITT Population .  All available data 

Protocol C601
Diazoxide Choline Controlled-Release (DCCR)
Soleno Therapeutics, Inc. Page [ADDRESS_1168359] s
randomized in a 2:[ADDRESS_1168360] at the alpha=0.05 level of significance .
[IP_ADDRESS] Multiple Comparisons - Control of the Alpha Level
To control the alpha level for the primary and secondary efficacy analyses at 0.05, a hierarchical 
fixed sequence testing procedure will be used.  
12.3.2 Secondary Efficacy Analyses
Body fat mass will be analyzed using an ANCOVA model with change from baseline to Visit 7 
as the response, baseline as a covariate, and treatment group and the randomization stratification variables as factors.
The Clinical Global Impression of Improvement and Caregiver Global Impression of Change
will be compared between treatment groups using the Cochran-Mantel-Haenszel (CMH) mean score test with modified ridit scores, strati fied by [CONTACT_449097].
Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 73 of 132 
Confidential Information   11 June 2019  12.4 Subgroup Analyses  
Analyses of the primary, selected secondary and /or selected exploratory endpoints may be 
performed using the fol lowing subgroups:  gender, baseline HQ -CT score , PWS genetic 
subtype /subclass ,  
  Other subgroup analyses may be conducted.  
12.[ADDRESS_1168361] dose of study drug will be 
used as the baseline for a ll analyses.  
All safety data will be summarized by [CONTACT_840917].  
12.5.1  Adverse Events  
Adverse events will be coded using MedDRA. A treatment -emergent AE (TEAE) is defined as 
an AE that starts or worsens at or during the  time of or after the first study drug administration 
through the Visit 7.  
12.5.2  Clinical Laboratory Evaluations  
All numeric laboratory data including chemistry (including liver enzyme of ALT, AST, and 
GGT) and hematology tests will be summarized at each visit as well as changes from baseline 
using summary statistics.  In addition, the maximum post -baseline and minim um post -baseline 
values will be summarized.  
Laboratory values will be categorized as normal, high, and low, based on normal ranges.  Shift 
from baseline will be summarized at each post -baseline visit.  
  
 
 
 
 
 
 
 

Protocol C601
Diazoxide Choline Controlled-Release (DCCR)
Soleno Therapeutics, Inc. Page 74 of 132
Confidential Information 11 June 201912.5.4 ECG Parameters
Descriptive statistics for heart rate, RR interval, P R interval, QRS interval, QT interval, and QT 
interval corrected with Fridericia‚Äôs (QTcF) formula and the change from baseline to each post -
baseline visit will be presented.  Changes in morphology will be captured in text.  
12.5.[ADDRESS_1168362]-baseline values  will also be summarized by [CONTACT_1570].
Shift tables may also be presented.  Clinically significant vital signs will be identified in the 
eCRF and will be listed.
Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 75 of 132 
Confidential Information   11 June 2019    
 
 
  
   
  
  
 
 
12.7 Termination Criteria  
The DSMB may recommend stoppi[INVESTIGATOR_840894] (See Section 6.7).  Potential study discontinuation 
reasons include:  
‚Ä¢ The sponsor determines that it is unsafe to continue because of an unexpected safety 
signal not otherwise clinically anticipated in randomized subjects without relevant 
medical history  
‚Ä¢ Significant i mbalance in rate of serious, unexpected adverse reactions that, independent 
of study drug, are not clinically anticipated in subject s randomized to DCCR versus 
placebo in subject s without relevant medical history  
‚Ä¢ Significant i mbalance in rate of serious ad verse reactions that, independent of study drug, 
are not clinically anticipated in subject s randomized to DCCR versus placebo in subject s 
without relevant medical history  
If such issues arise, Soleno will, in consultation with the DSMB, Investigators, appr opriate 
regulatory authority(ies), and/or IRBs /IECs , take the steps necessary to modify or discontinue the 
study . 
12.8 Deviation Reporting  
Changes made to the Statistical Analysis Plan (SAP) after it has been signed but prior to database 
lock will be documented  in an amendment to the Statistical Analysis Plan.  Any important 
changes made to the analysis after database lock will be described in the clinical study report 
(CSR).   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168363] ACCESS T O SOURCE DATA/DOCUMEN TATION  
Site visits will be conducted by [CONTACT_840918](s) of Soleno to inspect study data, 
subject ‚Äôs medical records, and eCRFs in accordance with current GCPs and respective national 
and local government regulations and guid elines (if applicable). The Investigator and Institution 
will permit authorized representatives of Soleno, its designees, the national health authorities, 
local authorities, and IRB /IEC  direct access to source data/documents , with the exception of the 
responses to the HQ -CT and Global Impression Questions during the course of the study as 
described in Section 6.3.[ADDRESS_1168364] study -related monitoring, audits, IRB /IEC  review, and 
regulatory inspections.  
14.0 QUALITY CONTROL AND QUALITY ASSURANCE  
Soleno will ensure that the study is conducted,  and data are generated, documented (recorded), 
and reported in compliance with t he protocol, GCP, and applicable regulatory requirement s. 
Quality control will be applied at each stage of data handling to ensure that all data are reliable 
and have been processed (e.g., monitoring to review source documents/ subject ‚Äôs charts against 
eCRF s, development of a monitoring plan, data management system with appropriate logic 
checks, quality control review of the database prior to database lock, quality control procedures 
to confirm accurate table, listings, etc.).    
Audits may be performed as p art of implementing quality assurance. Audits will evaluate study 
conduct, data/record integrity, and/or compliance with the protocol, standard operating 
procedures, GCP, and applicable regulatory requirements.  
The study will be registered on ClinicalTria ls.gov by [CONTACT_840919].  
15.0 ETHICAL CONSIDERATIO NS 
This study will be conducted according to applicable national standards for protection of human 
subjects and  Good Clinical Practice  including but not limited to US regulations 21 CFR 50, 56, 
312, Regulation EU 536/2 014, Directive 2005/28/EC,  Regulation EU 2016/679, and ICH Topic s 
E2A, E2B(R3),  E6(R2), and E11(R1 ). 
IRB/IEC approval will be obtained for the protocol, informed consent form, assent form, and all 
information provided to the caregiver / subject  prior to th eir use in the study.  No study site will 
receive study drug prior to obtaining IRB/IEC approval for the study.  
Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 77 of 132 
Confidential Information   11 June 2019  All parent (s) / legal guardian (s) of prospective subject s for this study will be provided a n 
informed consent form that describes this study and  provid es sufficient information for them to 
make an informed decision about their child‚Äôs participation in this study.  As applicable, 
prospective subject s will be provided an assent form that describes this study and provides 
sufficient information for them to provide assent to participate in the study.  The informed 
consent form and assent form will be submitted with the protocol for review and approval b y the 
IRB/IEC .  The formal consent and assent, as applicable, of a subject ‚Äôs participation , using the 
IRB/IEC -approved informed consent form, will be obtained before that subject  is submitted to 
any study procedure.  The parent(s) / legal guardian(s) and subject  will be given adequate time to 
review the patient information and informed consent form, given the opportunity to ask 
questions, and understand that if they decline to participate in the study, the future care of the 
subject  will not change. The informed consent form must be signed by [CONTACT_7071](s) /  legal 
guardian(s) and the assent form must be signed by [CONTACT_423] . The  investigator -designated 
research professional obtaining the consent  and assent must also sign the informed consent form 
and assent  form. Copi[INVESTIGATOR_840895] / legal guardian.  
16.[ADDRESS_1168365] maintain adequate records for the study including completed eCRFs, data 
correction forms, original source documents including certified copi[INVESTIGATOR_840896], signed ICFs, drug accountability records, AE reports, screening and enrollment logs, 
correspondence with the IRB /IEC  and Soleno or designee and other pertinent data and 
information.  Essential documents must be retained for [ADDRESS_1168366] approval of a 
marketing application in an International Conference on Harmonization (ICH) region and until 
there are no pending or contemplated marketing applications in an ICH regio n, or at least [ADDRESS_1168367] storage is changed (e.g. the Investigator leaves the institution where 
the study was conducted). In order to ensure that documents are not inadvertently destroyed 
prematurely, please contact [CONTACT_840920] -related documents.  
Data obtained from this study , including subject identity information,  will be handled, processed, 
stored, and retained in accordance with applicable laws, regulations, and guidance s. 
17.0 PUBLICATION PLAN  
The results of this clinical study may be used by [CONTACT_840921]/or regions participating in this study , or other countries  or 
regions , or for public dissemination in the form of papers, abstracts, posters, or other information 
Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page [ADDRESS_1168368] 45 days before their submi ssion or release 
or as specified in separate  written agreements.   
  
Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 79 of 132 
Confidential Information   11 June 2019  18.0 REFERENCES  
 
 (1)  Butler M, Lee P, Whitman BE. Clinical Findings and Natural History of Prader -Willi 
Syndrome. Management of Prader -Willi Syndrome . Springer [LOCATION_001]; 2006. 3 -48. 
 (2)  Buiting K, Horsthemke B. Molecular Genetic Findings in Prader -Willi Syndrome. In: 
Butler MG, Lee PDK, Whitman BY, editors. Management of Prader -Willi 
Syndrome .[LOCATION_001]: Springer Science+Business Media, Inc.; 2006. 58 -73. 
 (3)  McCandless SE. Clinical report -health supervision for children with Prader -Willi 
syndrome. Pediatrics  2011;127(1):195 -204. 
 (4)  Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H. Population prevalence 
and estimated birth incidence and mortality rate for people with Prader -Willi syndrome in 
one [LOCATION_006] Health Region. J Med Genet  2001;38(11):792 -798. 
 (5)  Dykens E M, Roof E, Hunt -Hawkins H. Cognitive and adaptive advantages of growth 
hormone treatment in children with Prader -Willi syndrome. J Child Psychol Psychiatry  
2017;58(1):64 -74. 
 (6)  Foundation for Prader -Willi Research. Prader -Willi Syndrome "Patient Voices"  Online 
Survey and Results.  1 -80. 2014.  
 (7)  Qi Y, Purtell L, Fu M et al. Snord116 is critical in the regulation of food intake and body 
weight. Sci Rep  2016;6:[ZIP_CODE].  
    
 
 
    
  
    
 
    
 
    
 
    
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 80 of 132 
Confidential Information   11 June 2019      
 
    
 
 
     
    
 
 
    
 
     
  
   
  
    
 
    
 
 
 
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 81 of 132 
Confidential Information   11 June 2019    
  
 
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 82 of 132 
Confidential Information   11 June 2019    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 83 of 132 
Confidential Information   11 June 2019    
  
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 84 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 85 of 132 
Confidential Information   11 June 2019   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 86 of 132 
Confidential Information   11 June 2019   
  
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 87 of 132 
Confidential Information   11 June 2019   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 88 of 132 
Confidential Information   11 June 2019   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 89 of 132 
Confidential Information   11 June 2019   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 90 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 91 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 92 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 93 of 132 
Confidential Information   11 June 2019   
  
 
 
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 94 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 95 of 132 
Confidential Information   11 June 2019   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 96 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 97 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 98 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 99 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 100 of 132 
Confidential Information   11 June 2019   
  
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 101 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 102 of 132 
Confidential Information   11 June 2019   
  
 
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 103 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 104 of 132 
Confidential Information   11 June 2019   
  
  
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 105 of 132 
Confidential Information   11 June 2019   
 
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 106 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 107 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 108 of 132 
Confidential Information   11 June 2019   
  
 
 
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 109 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 110 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 111 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 112 of 132 
Confidential Information   11 June 2019    
  
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 113 of 132 
Confidential Information   11 June 2019    

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 114 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 115 of 132 
Confidential Information   11 June 2019   
 

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 116 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 117 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 118 of 132 
Confidential Information   11 June 2019   
  
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 119 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 120 of 132 
Confidential Information   11 June 2019   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 121 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 122 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 123 of 132 
Confidential Information   11 June 2019   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 124 of 132 
Confidential Information   11 June 2019    
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 125 of 132 
Confidential Information   11 June 2019    

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 126 of 132 
Confidential Information   11 June 2019   

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 127 of 132 
Confidential Information   11 June 2019    
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 128 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 129 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 130 of 132 
Confidential Information   11 June 2019  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 131 of 132 
Confidential Information   11 June 2019   
  
 
  

Protocol C601  
Diazoxide Choline Controlled -Release (DCCR)  
 
Soleno Therapeutics, Inc.   Page 132 of 132 
Confidential Information   11 June 2019  

Soleno Therapeutics, Inc. Page 2 of 2
Confidential InformationSTATISTICAL ANAL YSIS PLAN APPROVAL
Protocol: C601
ADDENDUM
